FibroBiologics’ (FBLG) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a research note published on Thursday morning,Benzinga reports. The firm currently has a $12.00 target price on the stock.

FBLG has been the subject of a number of other research reports. D. Boral Capital reissued a “buy” rating and issued a $16.00 target price on shares of FibroBiologics in a research note on Friday, December 27th. Rodman & Renshaw started coverage on FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 price objective for the company. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Trading Down 4.7 %

Shares of NASDAQ:FBLG opened at $1.23 on Thursday. The company’s fifty day moving average is $1.93 and its 200 day moving average is $2.43. FibroBiologics has a 52 week low of $1.06 and a 52 week high of $15.50.

Institutional Investors Weigh In On FibroBiologics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Intech Investment Management LLC bought a new position in shares of FibroBiologics during the fourth quarter valued at approximately $25,000. Virtu Financial LLC purchased a new position in FibroBiologics during the 4th quarter valued at $30,000. The Manufacturers Life Insurance Company bought a new position in FibroBiologics in the 3rd quarter worth $32,000. Raymond James Financial Inc. purchased a new stake in shares of FibroBiologics in the 4th quarter worth about $37,000. Finally, Jane Street Group LLC bought a new stake in shares of FibroBiologics during the 3rd quarter valued at about $37,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.